JNJ

227.46

+0.25%↑

ISRG

503.04

-3.51%↓

ABT

105.97

-0.11%↓

MDT

100.49

-0.34%↓

A

132.5

-1.62%↓

JNJ

227.46

+0.25%↑

ISRG

503.04

-3.51%↓

ABT

105.97

-0.11%↓

MDT

100.49

-0.34%↓

A

132.5

-1.62%↓

JNJ

227.46

+0.25%↑

ISRG

503.04

-3.51%↓

ABT

105.97

-0.11%↓

MDT

100.49

-0.34%↓

A

132.5

-1.62%↓

JNJ

227.46

+0.25%↑

ISRG

503.04

-3.51%↓

ABT

105.97

-0.11%↓

MDT

100.49

-0.34%↓

A

132.5

-1.62%↓

JNJ

227.46

+0.25%↑

ISRG

503.04

-3.51%↓

ABT

105.97

-0.11%↓

MDT

100.49

-0.34%↓

A

132.5

-1.62%↓

Search

Charles River Laboratories International Inc

Aperta

SettoreSettore sanitario

212.07 -1.63

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

209.49

Massimo

217.74

Metriche Chiave

By Trading Economics

Entrata

2.9M

56M

Vendite

-27M

1B

EPS

2.43

Margine di Profitto

5.529

Dipendenti

18,700

EBITDA

-23M

198M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+0.92% upside

Dividendi

By Dow Jones

Utili prossimi

18 feb 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

2.1B

11B

Apertura precedente

213.7

Chiusura precedente

212.07

Notizie sul Sentiment di mercato

By Acuity

27%

73%

51 / 352 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bullish Evidence

Charles River Laboratories International Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

28 gen 2026, 23:51 UTC

Utili

Correction to Samsung Fourth-Quarter Net Profit Article

28 gen 2026, 23:49 UTC

Azioni calde

Stocks to Watch: Meta, IBM, Las Vegas Sands, Whirlpool

28 gen 2026, 23:19 UTC

Utili

Samsung's Fourth-Quarter Net Profit Beats Consensus

28 gen 2026, 22:43 UTC

Utili

Waste Management Logs Higher 4Q Profit as Revenue Rises

29 gen 2026, 00:00 UTC

Acquisizioni, Fusioni, Takeovers

Diller's Overture Came Before Warner Unveiled Split Plans, Source Says -- WSJ

29 gen 2026, 00:00 UTC

Acquisizioni, Fusioni, Takeovers

Warner Says CNN Wasn't and Isn't for Sale -- WSJ

29 gen 2026, 00:00 UTC

Acquisizioni, Fusioni, Takeovers

Barry Diller Told Warner Bros. Discovery He Is Interested in Buying CNN -- WSJ

29 gen 2026, 00:00 UTC

Acquisizioni, Fusioni, Takeovers

Barry Diller Approached Warner Bros. Discovery Last Year About Buying CNN, Sources Say -- WSJ

28 gen 2026, 23:49 UTC

Discorsi di Mercato

Nikkei May Rise as Weaker Yen Supports Earnings Hopes -- Market Talk

28 gen 2026, 23:30 UTC

Discorsi di Mercato

Tesla to Use Car Factory for Robot Aims -- Market Talk

28 gen 2026, 23:28 UTC

Utili

Microsoft's Earnings Surge, Elevated by Cloud Business -- 3rd Update

28 gen 2026, 23:26 UTC

Utili

Meta Reports Record Sales, Massive Spending Hike on AI Buildout -- 2nd Update

28 gen 2026, 23:21 UTC

Utili

Microsoft Stock Falls Despite Earnings Beat. Cloud Growth Slowed Slightly. -- Barrons.com

28 gen 2026, 23:18 UTC

Utili
Acquisizioni, Fusioni, Takeovers

Tesla to Invest $2 Billion in Elon Musk's xAI -- Update

28 gen 2026, 22:58 UTC

Utili

Tesla to Invest $2 Billion in Elon Musk's xAI -- Update

28 gen 2026, 22:48 UTC

Discorsi di Mercato

Woodside Energy Has Form With Conservative Production Guidance -- Market Talk

28 gen 2026, 22:45 UTC

Utili

Samsung Electronics 2025 Net KRW45.207T Vs. Net KRW34.451T >005930.SE

28 gen 2026, 22:44 UTC

Utili

Samsung Electronics 2025 Oper Pft KRW43.601T Vs. Pft KRW32.726T >005930.SE

28 gen 2026, 22:43 UTC

Utili

Samsung Electronics 2025 Rev KRW333.606T Vs. KRW300.871T >005930.SE

28 gen 2026, 22:41 UTC

Utili
Azioni calde

Earnings in Focus Wednesday: Microsoft, Tesla, Meta, Starbucks -- WSJ

28 gen 2026, 22:41 UTC

Discorsi di Mercato

Rising AUD Typically Sees Australian Stocks Outperform -- Market Talk

28 gen 2026, 22:41 UTC

Utili

Meta Stock Rises on Strong Earnings. Expenses Are Mounting. -- Barrons.com

28 gen 2026, 22:40 UTC

Utili

Samsung Electronics 4Q Net Profit Beat FactSet-Compiled Consensus

28 gen 2026, 22:39 UTC

Utili

Samsung Electronics 4Q Net KRW19.642T Vs. Net KRW7.754T >005930.SE

28 gen 2026, 22:38 UTC

Utili

Samsung Electronics 4Q Oper Pft KRW20.074T Vs. Pft KRW6.493T >005930.SE

28 gen 2026, 22:37 UTC

Utili

Samsung Electronics 4Q Rev KRW93.837T Vs. KRW75.788T >005930.SE

28 gen 2026, 22:35 UTC

Utili

Microsoft Stock Falls Despite Earnings Beat. Cloud Growth Slowed Slightly. -- Barrons.com

28 gen 2026, 22:26 UTC

Discorsi di Mercato
Utili

Meta's Rising CapEx is Fueled by High Pay for AI Workers -- Market Talk

28 gen 2026, 22:20 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

28 gen 2026, 22:20 UTC

Discorsi di Mercato

Woodside Energy's Oil Assets Blamed for Guidance Miss -- Market Talk

Confronto tra pari

Modifica del prezzo

Charles River Laboratories International Inc Previsione

Obiettivo di Prezzo

By TipRanks

0.92% in crescita

Previsioni per 12 mesi

Media 221.55 USD  0.92%

Alto 265 USD

Basso 170 USD

Basato su 13 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Charles River Laboratories International Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

13 ratings

9

Acquista

4

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

117.16 / 144.77Supporto e resistenza

A breve termine

Strong Bullish Evidence

A termine intermedio

Weak Bullish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

51 / 352 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat